A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Recruiting now · Phase 1/Phase 2

Conditions studied: EGFR Inhibitor-associated Rash

In brief

The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess efficacy signals of ATR04-484. Researchers will compare treatment of ATR04-484 to its vehicle. Participants will: * Apply ATR04-484 or vehicle daily for 28 days * Visit the clinic periodically for evaluation and sample collection

Key facts

Study ID
NCT06830863
Run by
Azitra Inc.
People needed
32
Starts
2025-08-25
Expected to finish
2027-02-15
Last updated by the study team
2026-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.